Who are Edaravone Dexborneol Sublingual Tablets's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/edaravone-dexborneol-sublingual-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Edaravone Dexborneol Sublingual Tablets — Competitive Intelligence Brief

Edaravone Dexborneol Sublingual Tablets (Edaravone Dexborneol Sublingual Tablets) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Free radical scavenger with permeation enhancer. Area: Neurology.

phase 3 Free radical scavenger with permeation enhancer Hydroxyl radicals and reactive oxygen species (ROS) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Edaravone Dexborneol Sublingual Tablets (Edaravone Dexborneol Sublingual Tablets) — Peking Union Medical College Hospital. Edaravone is a free radical scavenger that reduces oxidative stress and neuroinflammation, while dexborneol enhances absorption and bioavailability through sublingual delivery.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Edaravone Dexborneol Sublingual Tablets TARGET	Edaravone Dexborneol Sublingual Tablets	Peking Union Medical College Hospital	phase 3	Free radical scavenger with permeation enhancer	Hydroxyl radicals and reactive oxygen species (ROS)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Free radical scavenger with permeation enhancer class)

Peking Union Medical College Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Edaravone Dexborneol Sublingual Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/edaravone-dexborneol-sublingual-tablets. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab